
US-based Eli Lilly is upgrading its 2022 revenue outlook in connection with the company’s first quarterly report on Thursday.
The Novo Nordisk rival within the diabetes area is now expecting year-ending revenue to reach USD 28.8–29.3bn. A prior forecast stated USD 27.8–28.3bn, and the upward adjustment therefore surpasses the analyst consensus estimate of USD 28.43bn, which was compiled by Bloomberg News.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app